SUBSCRIBE: Print / Digital / eNewsletter
Rho kinase inhibitors—the newest drugs introduced for treating glaucoma—"get to the heart of the matter” by targeting specific glaucomatous abnormalities, such as trabecular meshwork outflow, said Yvonne Ou, MD.
New technology is good if it does what it purports to do and sometimes goes beyond that.
This article was reviewed by Prof. Gus Gazzard, FRCOpthMA, MBBCHIR, MD
At Glaucoma 360 in San Francisco, Terri Pickering, MD, tolds attendees that artificial intelligence is a hot topic, with room to expand in the future.
At Glaucoma 360 in San Francisco, Terri Pickering, MD, tolds attendees that artificial intelligence is a hot topic, with room to expand in the future.
During the Glaucoma 360 annual meeting, Dake K. Heuer, MD, delivered the Shaffer-Hetherington-Hoskins Lecture Keynote address, titled “Risk Factors for Glaucoma Progression.”
Delivering the Drs. Henry and Frederick Sutro Memorial Lecture, David W. Parke II, MD, CEO of the American Academy of Ophthalmology, points out that patients and physicians can benefit from innovations in treatment. However, health policy and economics often can stand in the way of innovation.
The Charity event kicks off the three-day program, focusing on melding medicine, industry, research, and philanthropy.
This article was reviewed by Joel S. Schuman, MD
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
